870249-29-9

Basic information

• Product Name: Ethanol, 2,2'-[[2-(1-methylethoxy)phenyl]imino]bis-
• CAS NO: 870249-29-9
• Molecular Formula: C13H21NO3
• Molecular Weight: 239.315
• Mol File: 870249-29-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Ethanol, 2,2'-[[2-(1-methylethoxy)phenyl]imino]bis-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanol, 2,2'-[[2-(1-methylethoxy)phenyl]imino]bis-(870249-29-9)
• EPA Substance Registry System: Ethanol, 2,2'-[[2-(1-methylethoxy)phenyl]imino]bis-(870249-29-9)

Safety Data

• Hazardous Substances Data: 870249-29-9(Hazardous Substances Data)

Upstream product

• 38753-50-3 1-isopropoxy-2-nitrobenzene 
• 29026-74-2 2-isopropoxy-phenylamine 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 870249-31-3 4-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-cyclohexylamine 

Relevant articles and documents

ADRENERGIC RECEPTOR ANTAGONISTS

This invention relates to α1a and/or α1d adrenergic receptor antagonists. Compounds disclosed herein can function as α1a and/or α1d adrenergic receptor antagonist and can be used for the treatment of diseases or disorder mediated through α1a and/or α1d adrenergic receptors. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia and the related symptoms thereof. Compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without benign prostatic hyperplasia. Processes for the preparation of compounds disclosed herein, pharmaceutical compositions containing the compounds disclosed herein, and methods of treating benign prostatic hyperplasia or related symptoms thereof are also provided. Formula (I) Its pharmaceutically acceptable acid addition salts,pharmaceutically acceptable solvates, enantiomers, diastereomers, N-oxides, polymorphs or metabolites,wherein; A represents a Formula (F.a or ,F.b or F.c wherein) N represents 1 or 2; Y represents cycloalkyl (C5-C7) group; optionally substituted with halogen atom(s) or lower alkyl (C1-C4) group; and R is selected from optionally substituted non_aromatic or aromatic monocyclic or bicyclic ring system having 0 to 4 heteroatom(s),the substituent(s) may be selected from the group consisting of halogen, lower alkyl (C1-C4),halogenated lower alkyl (C1-c4),cyano, hydroxy, lower alkoxy (C1-C4),cycloalkoxy (C3-C6),amino,lower alkylamino (C1-C4) and lower alkylamino (C1-C4) carbonyl group.